VKTX — Viking Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $4.19bn
- $3.48bn
- 59
- 21
- 34
- 31
Annual income statement for Viking Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 42.7 | 55.7 | 70.4 | 101 | 151 |
| Operating Profit | -42.7 | -55.7 | -70.4 | -101 | -151 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -39.5 | -55 | -68.9 | -85.9 | -110 |
| Net Income After Taxes | -39.5 | -55 | -68.9 | -85.9 | -110 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -39.5 | -55 | -68.9 | -85.9 | -110 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -39.5 | -55 | -68.9 | -85.9 | -110 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.544 | -0.712 | -0.896 | -0.91 | -1.01 |